Research programme: antibacterials - Antex Pharma/Lyotropic Therapeutics
Latest Information Update: 23 Mar 2007
At a glance
- Originator Antex Pharma; Lyotropic Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 23 Mar 2007 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
- 13 May 2003 No development reported - Preclinical for Bacterial infections in USA (unspecified route)
- 11 Oct 2000 Preclinical development for Bacterial infections in USA (Unknown route)